Bortezomib increases immunotherapy efficacy through enhancement of STING and IFN-γ signaling in lung adenocarcinoma

However, the clinical trails of BTZ alnoe or BTZ combinated with other chemotherapy have failed. Here, we reported that BTZ enhanced the anti-tumor efficacy of PD1/PDL1 blockade therapy in a Lewis lung carcinoma (LLC) tumor model.

In both in vitro and in vivo assay, our data showed that BTZ activated STING pathway and increased the responsiveness of tumor cells to IFN-γ through the upregulation of surface IFN-γ receptor I (IFNGR1), which contributed to the superior anti-tumor efficacy of BTZ in combination with PD1/PDL1 inhibitors in lung adenocarcinoma.